Press "Enter" to skip to content

Coagulation Disorders Market To 2016 – Switch From Episodic Treatment To Prophylactic Treatment Will

In 2009, the global coagulation disorders market was estimated to be worth $5.5 billion, representing a cumulative annual growth rate (CAGR) of 6.3% between 2001 and 2009. By 2016, the global coagulation disorders market is estimated to reach $7.7 billion, indicating a CAGR of 5% between 2009 and 2016. The major reason for the reduced growth rate is the expected decline in the annual cost of treating coagulation disorders after 2010.

For Sample Pages, please click or add the below link to your browser:

The current global coagulation disorders market is significantly consolidated, as the top two players in the market, Baxter and Bayer, control approximately 56% of the market. Baxter is the current market leader with its blockbuster product, Advate, controlling 29% of the total coagulation disorders market, and FEIBA VH with a 4.6% market share in 2009. Bayer follows with a 22% market share, primarily due to its top selling hemophilia A product Kogenate FS. NovoNordisks third position is attributed to the sales of NovoSeven; it does not have any significant presence in the branded coagulation disorders market apart from this. Pfizer and CSL Behring are the fourth and the fifth largest players, primarily due to ReFacto, Xyntha and Helixate FS indicated for hemophilia A, and BeneFIX indicated for hemophilia. The companies control 15% and 8% of the total coagulation disorders market, respectively.

The current coagulation disorders pipeline contains 90 projects across five major indications. Hemophilia A and hemophilia B, currently accounting for more than two-thirds of the total coagulation disorders market, are the key therapy areas of focus in the current pipeline, with approximately 64% of the current coagulation disorders pipeline concentrating on these two indications. About 20 molecules, representing 22% of the current coagulation disorders pipeline, are in early stages of development for hemophilia. These drugs have not been classified for hemophilia A and hemophilia B.

GBI Research, the leading business intelligence provider, has released its latest research, Coagulation Disorders Market to 2016 – Switch from Episodic Treatment to Prophylactic Treatment Will Increase Cost of Hemophilia Therapy. It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global coagulation disorders therapeutics market. The report analyzes the markets for coagulation disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales value and annual cost of therapy are forecast until 2016 for key geographies in the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers and acquisitions (M&A) and licensing agreements that shape the global markets.

For further details, please click or add the below link to your browser:

Visit our report store:

For more details contact:

North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782